Subscribe To

Price Alert Latest News Economic Calendar News

VYYRF / Voyageur Pharmaceuticals issues deferred share units to directors under equity incentive compensation plan

Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) said it has issued 125,322 Deferred Share Units (DSUs) to directors under its fixed 10% equity incentive compensation plan adopted by the company following receipt of shareholder approval on June 28, 2021. Each DSU represents a right of the holder to receive one common share of the corporation effective as of the date that the holder ceases service as a director of the company. Read More

Demo Live Account See Partner Details

Content Topics

Voyageur

Pharmaceuticals

Issues

Deferred

Units

Directors

Equity

Incentive

Compensation

Stock

VYYRF

Posted: Dec 5 2022, 06:46

Author Name: Proactive Investors

VYYRF News

By Proactive Investors
September 14, 2023

Voyageur Pharmaceuticals achieves milestone in the development of HDXBa barium contrast media

Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) told investors it has completed the formulation and engineering for production processing of its dr

By Proactive Investors
August 1, 2023

Voyageur Pharmaceuticals appoints seasoned executive to board; files interim financial statements

Voyageur Pharmaceuticals said it is adding experienced finance and accounting professional Kevin R. McBeth to its board following the retirement of

By Proactive Investors
June 16, 2023

Large-scale fullerene production opens up world of possibilities in medicine, electronics

A Calgary-based company has unveiled a new process to produce fullerenes and their derivatives, which are among the world's most valuable materials, o

By Proactive Investors
June 12, 2023

Voyageur Pharmaceuticals says white paper highlights SmoothX's potential as oral contrast agent

Voyageur Pharmaceuticals has highlighted a new white paper that outlines the imaging properties of its product SmoothX and its potential to optimize a

By Proactive Investors
May 31, 2023

Voyageur Pharmaceuticals completes field work at Frances Creek project in British Columbia

Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) announced that it has successfully completed the environmental and geotechnical field work at its F

By Proactive Investors
May 24, 2023

Voyageur Pharmaceuticals unveils pioneering agreement with Rain Cage Carbon

Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) has announced a new development and license agreement with Rain Cage Carbon Inc to develop cuttin

By Proactive Investors
April 13, 2023

Voyageur Pharmaceuticals aims to be the first vertically-integrated North American supplier of medical imaging contrast agents

Amid supply chain challenges, demand for medical imaging contrasts such as barium sulfate and iodine which are used by radiologists to diagnose patien

By Proactive Investors
April 4, 2023

Voyageur Pharmaceuticals reports positive comparative study of SmoothX barium contrast media for CT imaging

Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) said it has completed comparative studies of its SmoothX barium contrast media versus ReadiCat 2%

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.